Mistral Large 4 Opens Weights

The strongest signal is the widening gap between AI capability demos and real-world validation: developers gain more control over powerful models, but medical deployment still needs outcome evidence.

• –Open weights enable self-hosting, customization, and deployment through tools such as vLLM and SGLang, though Mistral’s license requires separate permission for model-as-a-service offerings.
• –Mistral reports major coding and cybersecurity gains with improved token efficiency, but independent evaluations and infrastructure costs should determine practical value.
• –The Kenya trial covered 9,691 patients across 16 facilities, with treatment failure at 2.2% under LLM assistance versus 2.0% for controls.
• –Developers should separate benchmark performance, deployability, and clinical efficacy when evaluating AI systems for high-stakes workflows.